CJC-1295 with DAC vs Turinabol
Well Studied vs Moderate Research
monitor Mechanism-based · 51% Both CJC-1295 with DAC and Turinabol can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed.
Molecular Data
CJC-1295 with DAC Turinabol
Weight 3,647.28 Da 334.88 Da
Half-life 6-8 days ~16 hours
Chain 30 amino acids —
Type GHRH analog with DAC 17-alpha-alkylated anabolic-androgenic steroid (C20H27ClO2)
Key Benefits
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
Turinabol
01 Promotes lean, dry muscle gains without water retention or bloating
02 Does not aromatize to estrogen, eliminating risk of gynecomastia and estrogen-related side effects
03 Favorable anabolic-to-androgenic ratio, reducing androgenic side effects relative to muscle-building potential
04 Enhances muscular endurance and recovery through increased red blood cell production
05 Increases strength without significant body weight gain, beneficial for weight-class athletes
06 Improves creatine phosphate resynthesis, supporting repeated high-intensity efforts
07 Relatively mild androgenic profile compared to most oral anabolic steroids
08 Produces slow, steady, maintainable gains rather than rapid temporary increases
Dosing Protocols
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
Turinabol
30-60 mg/day (male) / Split into 2 doses daily (morning and evening)
Side Effects
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
Turinabol
Hepatic stress with elevated liver enzymes (ALT, AST) -- moderate severity, dose- and duration-dependent
HDL cholesterol suppression (significant, often 30-50% reduction)
LDL cholesterol elevation
Suppression of endogenous testosterone production via HPG axis negative feedback
Mild gastrointestinal discomfort or nausea
Back pumps (lower back tightness during exercise, common with 17-alpha-alkylated compounds)
Oily skin and mild acne
Decreased appetite in some users
Contraindications
Diabetes history
Cancer history
Predisposed sleep apnea
Known or suspected prostate cancer
Breast cancer in males
Pregnancy or planned pregnancy (teratogenic risk)
Active liver disease or significant hepatic impairment
Pre-existing severe dyslipidemia or cardiovascular disease
Hypersensitivity to turinabol or related compounds
Research Evidence
CJC-1295 with DAC Turinabol
Status Well Studied Moderate Research
References 4 studies 5 studies
Latest 2025 June 2023
FDA Approved No No
Full CJC-1295 with DAC profile Full Turinabol profile CJC-1295 with DAC calculator Turinabol calculator
More comparisons: Testosterone
This comparison is for educational and research purposes only. Consult a healthcare professional before use.